Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating potential claims against BioAge Labs, Inc. following a class action complaint filed in January 2024. The investigation focuses on possible breaches of fiduciary duties by the company's board, particularly after BioAge announced the discontinuation of the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety issues. This announcement resulted in a dramatic decline in BioAge's stock price.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge Labs discontinued the STRIDES Phase 2 trial for azelaprag due to safety concerns.
  • The discontinuation of the trial led to a significant stock price decline from $20.09 to $4.65.
  • The investigation is based on allegations that BioAge's board may have breached fiduciary duties.

Full Press Release Details

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
If you are a long-term stockholder of BioAge, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the investigation about BioAge Labs, Inc.?

Bragar Eagel & Squire is investigating potential claims against BioAge regarding possible breaches of fiduciary duties by its board.

What triggered the class action against BioAge?

A class action complaint was filed after BioAge announced it would halt the STRIDES Phase 2 trial due to safety concerns.

What happened to BioAge's stock price recently?

BioAge's stock price dropped from $20.09 on December 6, 2024, to $4.65 the next day.

Who can join the investigation into BioAge?

Long-term stockholders of BioAge who have information or questions can participate in the investigation.

How can I contact the law firm for more information?

You can reach out via email at investigations@bespc.com or call (212) 355-4648.

Last updated: Jul 3, 2025